The FDA has approved J&J's (NYSE:JNJ) Invokana drug for treating type 2 diabetes in a new way by causing the body to excrete blood sugar via the urine rather than affecting the supply or use of insulin. The agency said J&J must carry out five post-marketing studies to determine whether the drug increases the risks of strokes, heart attacks and other side effects. Invokana is forecast to generate sales of $667M by 2016.
The FDA has approved J&J's (NYSE:JNJ) Invokana drug for treating type 2 diabetes in a new...
Recommended For You
About JNJ Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
JNJ | - | - |
Johnson & Johnson |